Magnetic Resonance Spectroscopy of Parkinson's Disease at 7 Tesla

University of Minnesota1 site in 1 country78 target enrollmentFebruary 2010

ConditionsParkinson's Disease

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Parkinson's Disease
Sponsor: University of Minnesota
Enrollment: 78
Locations: 1
Primary Endpoint: Magnetic resonance spectroscopy (MRS)
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study is looking for healthy controls and patients with Parkinson's (PD) to perform an MR scan.

The neurochemical profile of the SN of patients with PD as measured by high field MRS will differ from that of healthy controls, in that glutathione will be lower due to oxidative stress, lactate will be higher due to mitochondrial dysfunction, the gliosis markers myo-inositol and glutamine will be higher due to inflammation (glial activation) and N-acetylaspartate and glutamate will be lower due to neuronal loss/damage.
There will be a relationship between neurochemical changes and disease severity.

Registry

clinicaltrials.gov

Start Date

February 2010

End Date

February 2019

Last Updated

6 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

University of Minnesota

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Parkinson's disease Group
•Parkinson's disease (clinical diagnostic criteria)
•Age 45-75 years inclusive
•Able to safely undergo MRI scanning
•Absence of diabetes and smoking
•Capable of giving informed consent
•Healthy Control Group
•Age 45-75 years inclusive
•Able to safely undergo MRI scanning
•Absence of diabetes and smoking

Exclusion Criteria

•Parkinson's disease Group
•Dementia (clinically determined by PI Dr. Tuite)
•Diagnosis of atypical parkinsonism
•Inability to safely undergo MRI scanning
•Inability to give informed consent
•Unstable medical conditions
•Present smoker
•Diabetic (on oral or injectable medications for diabetes)
•Taken coenzyme Q10 or Vitamin E in the 2 weeks prior to the scan
•Does not meet age criteria

Outcomes

Primary Outcomes

Magnetic resonance spectroscopy (MRS)

Time Frame: Baseline

We will utilize optimized magnetic resonance spectroscopy (MRS) methodology to address theories of pathogenesis of Parkinson's disease (PD) by quantifying glutathione (GSH), lactate, glutamine and myo-inositol levels of the unilateral substantia nigra (SN) of healthy volunteers and patients with PD.